Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma

Toshiki Natazuka, Toru Yamaguchi, Tohru Murayama, Masaaki Fukase, Toshimitsu Matsui, Takashi Isobe, Kazuo Chihara

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

A 35-year-old male presented with chronic myelomonocytic leukemia (CMMoL) after 6.5 years of alkylating agent therapy for IgG-κ type multiple myeloma. The total dose of melphalan was 0.648 g. CMMoL was stable with weekly injection of α-interferon for one year. Thereafter, monocytosis and thrombocytopenia aggravated, and the patient died of disseminating intravascular coagulation. Prolonged drug therapy can induce CMMoL, as well as other myelodysplastic syndromes.

Original languageEnglish
Pages (from-to)263-265
Number of pages3
JournalInternational Journal of Hematology
Volume60
Issue number4
DOIs
StatePublished - Dec 1994
Externally publishedYes

Fingerprint

Dive into the research topics of 'Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma'. Together they form a unique fingerprint.

Cite this